Clinical Trial Update: Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Results from a Phase 3 trial evaluating daily everolimus in combination with trastuzumab and vinorelbine in HER2-positive locally advanced or metastatic breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Afinitor (everolimus)
• HERCEPTIN (trastuzumab)
• Navelbine (vinorelbine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-04-05